Spectrum Pharmaceuticals, Inc.
SPPI · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.05 | -0.19 | -0.57 |
| FCF Yield | -144.04% | -60.87% | -29.98% | -35.69% |
| EV / EBITDA | -0.73 | -0.74 | -2.24 | -2.43 |
| Quality | ||||
| ROIC | -118.44% | -247.83% | -116.86% | -66.39% |
| Gross Margin | 82.28% | 0.00% | 0.00% | 46.91% |
| Cash Conversion Ratio | 1.29 | 0.75 | 0.76 | 1.19 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -43.94% |
| Free Cash Flow Growth | 18.75% | 5.86% | 11.48% | -120.46% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 0.59 | 0.26 | 0.43 |
| Interest Coverage | -72.84 | 0.00 | 0.00 | 28.83 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,390.07 | 0.00 | 0.00 | -1,488.79 |